Real-world one-year overall survival among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan in the NAPOLI-1 based regimen

MLA

George P. Kim, et al. “Real-World One-Year Overall Survival among Patients with Metastatic Pancreatic Ductal Adenocarcinoma (MPDAC) Treated with Liposomal Irinotecan in the NAPOLI-1 Based Regimen.” Journal of Clinical Oncology, vol. 39, Jan. 2021, p. 392. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........4412a021a5f0c136b8019d41a0a88ae4&authtype=sso&custid=ns315887.

APA

George P. Kim, Andy Surinach, Laith Abushahin, & Paul Cockrum. (2021). Real-world one-year overall survival among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan in the NAPOLI-1 based regimen. Journal of Clinical Oncology, 39, 392.

Chicago

George P. Kim, Andy Surinach, Laith Abushahin, and Paul Cockrum. 2021. “Real-World One-Year Overall Survival among Patients with Metastatic Pancreatic Ductal Adenocarcinoma (MPDAC) Treated with Liposomal Irinotecan in the NAPOLI-1 Based Regimen.” Journal of Clinical Oncology 39 (January): 392. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........4412a021a5f0c136b8019d41a0a88ae4&authtype=sso&custid=ns315887.